Abstract:Recent studies in Alzheimer’s disease (AD) suggest that tau proteins spread through the brain following neuronal connections. Several mechanisms could be involved in this process: spreading between brain regions that interact strongly (functionally connected); through the pattern of anatomical connections (structural connectivity); or simple diffusion to spatially adjacent regions (Euclidean distance (EC)). We investigated this by modelling the tau‐spreading process on these different networks, and compared the modelled tau‐depositions with tau‐depositions at several stages of the AD continuum as measured with in‐vivo 18F‐flortaucipir PET. We collected 10‐minutes eyes‐closed, whole‐head magnetoencephalography (MEG) recordings from 82 subjects (Table‐1) with and without Aβ‐pathology (CSF‐Aβ42 and/or amyloid‐PET) from the Amsterdam Dementia Cohort. Subjects were classed as controls (subjective cognitive decline (SCD) Aβ‐,n=25), preclinical AD (SCD Aβ+,n=16), mild cognitive impairment (MCI) due to AD (n=16) and probable AD dementia (n=25). Tau propagation was modelled as an epidemic process (susceptible‐infected (SI) model) on structural networks (Exponential Distance Rule (EDR) or EC), or functional networks (corrected‐amplitude envelope correlation (AEC‐c) in alpha (8‐13Hz) and beta (13‐30Hz) bands) derived from source‐reconstructed MEG data. The group‐level control network was used as backbone for the SI‐model to predict tau spread in the next stages of the AD continuum; parameters were tuned to produce an optimum correlation to the group‐specific tau propagation patterns as measured with dynamic 130‐minutes 18F‐flortaucipir PET, according to 50 regions‐of‐interest (ROIs) in an adjusted version of the probabilistic Hammers atlas. Tau propagation was modelled to start from one seed region (ROI14), which was selected based on its reliability to accurately measure tau deposition. The functional network predicted tau‐spread with highest accuracy in the preclinical AD stage (AEC‐c alpha r=0.59; AEC‐c beta r=0.58), followed by the structural network (r=0.45) and simple diffusion (r=0.44), Figure‐1, Figure‐2, Figure‐3. Prediction accuracy declined for the MCI and AD dementia stages (AEC‐c alpha r=0.50 and r=0.33; AEC‐c beta r=0.40 and r=0.37; structural r=0.29 and r=0.25; diffusion r=0.29 and r=0.25, respectively). Using a relatively simple SI‐model we predicted tau propagation in preclinical AD with an accuracy of approximately 60%. Our results suggest that tau spreads through functional connections, rather than structural connections or simple diffusion.

appear resistant to trans-synaptic tau propagation

A model for mechanistic investigation of tau protein spread

A Drosophila model for mechanistic investigation of tau protein spread

Tau protein spreads through functionally connected neurons in Alzheimer’s disease

O3‐01‐05: in vitro measurements of tau aggregate elongation and fragmentation rates allow the modelling of prion‐like spreading in humans

Hyperactive neuronal networks facilitate tau spread in an Alzheimer's disease mouse model

A Novel Transgenic Mouse Line with Hippocampus-Dominant and Inducible Expression of Truncated Human Tau

Neurogenetic contributions to amyloid beta and tau spreading in the human cortex

Modeling Alzheimer'S Disease In Mouse Without Mutant Protein Overexpression: Cooperative And Independent Effects Of A Beta And Tau

Modeling Alzheimer’s Disease in Mouse without Mutant Protein Overexpression: Cooperative and Independent Effects of Aβ and Tau

Human iPSC-Derived Neuronal Model of Tau-A152T Frontotemporal Dementia Reveals Tau-Mediated Mechanisms of Neuronal Vulnerability.

Unique Pathological Tau Conformers from Alzheimer'S Brains Transmit Tau Pathology in Nontransgenic Mice

Humanized Tau Mice with Regionalized Amyloid Exhibit Behavioral Deficits but No Pathological Interaction

Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-like Tauopathy.

Differential compartmental processing and phosphorylation of pathogenic human tau and native mouse tau in the line 66 model of frontotemporal dementia

Tau depletion in human neurons mitigates Aβ-driven toxicity

Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration

Shaping the future of preclinical development of successful disease-modifying drugs against Alzheimer's disease: a systematic review of tau propagation models

Transcriptional programs mediating neuronal toxicity and altered glial-neuronal signaling in a knock-in tauopathy model

A novel tau‐based rhesus monkey model of Alzheimer's pathogenesis

Tau pathology spread in PS19 tau transgenic mice following locus coeruleus (LC) injections of synthetic tau fibrils is determined by the LC’s afferent and efferent connections